“The Science Exists. The Path Forward Is Clear.”
“Alzheimer’s treatment has forced families to choose between memory and quality of life for decades. Current drugs work—but not at the doses most people can tolerate. CNS-selective therapeutics change that equation entirely.”
Understand the Treatment Gap Get Free ResourcesThe Sub-Clinical Gap: Why Current Treatments Fall Short
Current Alzheimer’s medications work—but not at the doses most people can tolerate. The drugs prescribed today inhibit an enzyme that breaks down acetylcholine, a neurotransmitter essential for memory. The problem? To get meaningful benefit, you need 60-80% inhibition in the brain. At maximum tolerable doses, most patients achieve only 20-40%—leaving the majority of the therapeutic target untouched.
The result is a cruel compromise: take a dose low enough to avoid debilitating nausea and heart complications, but too low to meaningfully slow decline. Or push higher and sacrifice quality of life for marginal gains. For decades, families have been told this is simply the best we can do.
It isn’t.
Learn More60-80%
At maximum tolerable doses, current treatments leave 60-80% of the target enzyme still active in the brain.
A Better Path: CNS-Selective Therapeutics
What if a treatment could reach the brain without wreaking havoc on the rest of your body? That’s the promise of CNS-selective therapeutics—drugs designed to concentrate their effects in the central nervous system (brain and spinal cord) while sparing the heart, gut, and muscles from collateral damage.
Cnstyx (MSF – Methanesulfonyl Fluoride) is the leading example of this approach. Unlike legacy treatments that inhibit enzymes throughout your entire body, Cnstyx achieves therapeutic levels in the brain while allowing peripheral tissues to recover quickly. The result: the inhibition levels needed for real benefit, without the side effects that make current drugs intolerable.
“80% brain enzyme inhibition with minimal systemic effects—the therapeutic target legacy drugs can’t reach.”
For Families & Caregivers:
“You didn’t ask for this journey, but you don’t have to navigate it alone. Access free courses, practical resources, and a private community of people who truly understand.”
Get Support →For Healthcare Providers:
“The science behind CNS-selective therapeutics, explained. Clinical evidence, mechanism deep-dives, and resources you can share with patients and families.”
View Clinical Resources →Support the Mission:
“Every dollar accelerates education, advocacy, and research for treatments that don’t force families to choose between memory and quality of life.”
Donate →501(c)(3) Nonprofit
Peer-Reviewed Science
Transparent Funding
Connected to Memory Science Tech
Stay Informed
The science of Alzheimer’s treatment is evolving—and so is the conversation. Get research updates, new resources, and advocacy news delivered to your inbox. No spam, no fluff, just the information that matters.